Physician profile
Raza U Hashmi
NPI 1700089521
$17,344.42
in general payments reported to CMS, 2019-2025
40 companies · $3,467 in 2025
The $3,467 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $746 · 2021: $2,469 · 2022: $2,817 · 2023: $3,144 · 2024: $3,802 · 2025: $3,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,314.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,027.43 | 2019-2025 | Tavneos, Enbrel, Krystexxa |
| Abbvie INC. | $2,590.26 | 2019-2025 | |
| Ucb, INC. | $2,138.67 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,147.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,040.71 | 2019-2025 | |
| Janssen Biotech, INC. | $871.62 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $859.26 | 2020-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $777.36 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $599.13 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $550.81 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $526.89 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $495.52 | 2020-2025 | Acthar |
| Lilly USA, LLC | $431.07 | 2019-2024 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $413.12 | 2019-2025 | Orencia |
| Genentech USA, INC. | $368.37 | 2019-2025 | Actemra, Gazyva |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.